If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 9 of 9

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Objective
This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
Categories
Cancer, Ovary, Bladder, Gynecologic Cancers, Pancreas/Liver, Lip, Oral Cavity and Pharynx, Prostate and Urologic Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Esophagus, Thoracic Cancers, Early Phase/Multiple Disease Site Cancers

A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE

Objective
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)
Protocol No
ANTHOS-ANT-007
Categories
Cancer, Eye/Orbital Cancers, Skin Cancers, Cervix, Lip, Oral Cavity and Pharynx, Sarcoma, Other Gastrointestinal, Other Blood Related, Pancreas/Liver, Uterine, Other Respiratory, Gynecologic Cancers, Brain and Spine Cancers, Bladder, Lung, Head and Neck Cancers, Leukemia, Prostate, Esophagus, Thoracic Cancers, Colorectal, Hematologic/Blood Related Cancers, Gastrointestinal Cancers, Kidney, Endocrine Cancers, Prostate and Urologic Cancers, Multiple Myeloma, Breast Cancers

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Objective
Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)
Protocol No
AVEO-AV-299-23-301
Categories
Cancer, Lip, Oral Cavity and Pharynx, Head and Neck Cancers

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

Objective
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer, Other Skin, Thoracic Cancers, Gynecologic Cancers, Other Gastrointestinal, Early Phase/Multiple Disease Site Cancers, Lip, Oral Cavity and Pharynx, Melanoma, Skin, Esophagus, Bladder, Pancreas/Liver, Prostate, Skin Cancers, Kidney, Prostate and Urologic Cancers, Head and Neck Cancers, Colorectal, Gastrointestinal Cancers, Sarcoma, Breast Cancers

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Objective
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Protocol No
NRG-BN013
Categories
Cancer, Other Skin, Bladder, Colorectal, Cervix, Other Gynecologic, Breast Cancers, Esophagus, Prostate, Larynx, Other Gastrointestinal, Esophagus, Gynecologic Cancers, Other Respiratory, Melanoma, Skin, Prostate and Urologic Cancers, Pancreas/Liver, Eye/Orbital Cancers, Thoracic Cancers, Lip, Oral Cavity and Pharynx, Head and Neck Cancers, Gastrointestinal Cancers, Endocrine Cancers, Skin Cancers, Brain and Spine Cancers

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

Objective
Olanzapine vs Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Protocol No
ALLIANCE-A222004-ANOREXIA
Categories
Cancer, Cervix, Lip, Oral Cavity and Pharynx, Endocrine Cancers, Prostate and Urologic Cancers, Other Skin, Breast Cancers, Other Respiratory, Gastrointestinal Cancers, Uterine, Thoracic Cancers, Gynecologic Cancers, Sarcoma, Eye/Orbital Cancers, Skin Cancers, Larynx, Head and Neck Cancers, Brain and Spine Cancers

High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)

Objective
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Categories
Cancer, Lip, Oral Cavity and Pharynx, Cervix, Melanoma, Skin, Skin Cancers, Prostate and Urologic Cancers, Breast Cancers, Other Gastrointestinal, Gynecologic Cancers, Thoracic Cancers, Pancreas/Liver, Esophagus, Colorectal, Endocrine Cancers, Gastrointestinal Cancers, Sarcoma, Larynx, Brain and Spine Cancers, Head and Neck Cancers